Engineered T-Cells take on Hard-to-Treat blood cancers in first human trial
Disease control
Recruiting now
This early-phase study tests a new treatment called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis that has not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recog…
Phase: PHASE1 • Sponsor: CERo Therapeutics Holdings, Inc. • Aim: Disease control
Last updated May 17, 2026 06:48 UTC